Skip to main content

Advertisement

Table 3 Objective tumor response

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

  Platinum combination therapy (n = 24) n (%) Docetaxel monotherapy (n = 61) n (%) p value*
Complete response 0 (0) 1 (1.6) 0.30
Partial response 4 (16.7) 3 (4.9)  
Stable disease 10 (41.7) 31 (50.8)  
Progressive disease 9 (37.5) 24 (39.3)  
Not evaluable 1 (4.1) 2 (3.3)  
Response rate (%) 16.7 6.6 0.09
Disease control ratea (%) 58.3 57.4 0.82
  1. *Fisher’s exact test.
  2. aComplete response + partial response + stable disease.